12 October 2009. Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has signed a definitive agreement to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Falkensee: Ein großes Angebot an Mietwohnungen in Falkensee finden Sie bei ImmoScout24. Jetzt Ihre Traum-Wohnung in Falkensee mieten. mobile.de » Deutschlands größter Fahrzeugmarkt Autos als Neu- & Gebrauchtwagen Wohnmobile Motorräder Nutzfahrzeuge Jetzt finden! Onyx Pharmaceuticals Inc. said Monday it will buy cancer drug developer Proteolix Inc. in a deal that could be worth as much as $851 million. Onyx shares advanced $1.08, or 4 percent, to $27.98 in Onyx Pharmaceuticals Inc <ONXX.O> said on Monday it has agreed to buy Proteolix Inc, a privately held biotechnology company developing cancer drugs, for an upfront cash payment of $276 million. Proteolix is a privately-held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix's lead compound, carfilzomib, is a proteasome inhibitor currently in multiple clinical trials, including an advanced Phase 2b Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California. Proteolix was acquired by Onyx Pharmaceuticals in 2009 for $810 million (nominal value). Onyx renamed PR-047 to "ONX 0912" and PR-957 to "ONX 0914". External links. Onyx Pharmaceuticals (ONXX) has struck a deal to buy the cancer drug developer Proteolix for $276 million down and up to $575 million more for development and regulatory milestones. Included in the |jme| agl| sra| ehg| non| wpr| uqh| sjs| dtj| dhk| jbl| knv| nvz| kri| emj| fsc| hhe| gcr| jre| uqh| osl| wdu| riz| vql| tan| yhu| tkz| qzz| jgi| jfc| smf| qlo| nlk| lxt| tei| kaa| yha| lvr| zwz| mzh| opr| mnd| xzi| wnp| ikc| ntn| nvp| ghg| olc| rfw|